Breaks Categories: News

MondayMar 02, 2026 9:10 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer. Prof. Brown is a psychiatrist, neurologist and neuroscientist who studies the mechanisms of Transcranial Magnetic Stimulation (TMS) and their translation into clinical optimization. He serves as Medical Director of the McLean Hospital TMS Service, Director of TMS research and founding director of the Brain Stimulation Mechanisms Laboratory, with more than $20 million in federal funding from the National Institute of Mental Health and the Defense Advanced Research Projects Agency. At NRx, he will support development of mechanistically informed neuropsychiatric…

Continue Reading

ThursdayFeb 26, 2026 9:27 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease 

Soligenix (NASDAQ: SNGX) announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive recommendation for orphan drug designation of dusquetide, the active ingredient in SGX945, for the treatment of Behçet Disease, following review of recently published Phase 2a data demonstrating biological efficacy and safety. The recommendation now advances to the European Commission for ratification. The company noted that orphan designation in the European Union provides 10 years of market exclusivity upon approval, along with development incentives and centralized authorization access. SGX945 has previously received orphan drug and fast track designations from the U.S. Food and Drug Administration for Behçet Disease. To view the full press release, visit https://ibn.fm/tintJ About Soligenix Inc. Soligenix is…

Continue Reading

ThursdayFeb 26, 2026 9:10 am

BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets

Kairos Pharma (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., under which it would obtain worldwide rights to CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, oral type IIb c-MET kinase inhibitor targeting non-small cell lung cancer. The company said the proposed acquisition would expand its oncology pipeline with late-preclinical and Phase 1-ready candidates designed to address EGFR mutations and MET-driven resistance mechanisms in NSCLC, a multi-billion dollar market. Kairos indicated that dual inhibition of EGFR and MET pathways could overcome compensatory signaling and extend progression-free survival,…

Continue Reading

WednesdayFeb 25, 2026 2:07 pm

BioMedNewsBreaks — Anixa Biosciences, Inc. (NASDAQ: ANIX) CAR-T Co-Inventor To Keynote SCTR 2026 Retreat 

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology at Duke University School of Medicine and co-inventor of Anixa’s CAR-T technology, will deliver a keynote presentation at the South Carolina Clinical & Translational Research Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation on March 6, 2026. His remarks are expected to include discussion of Anixa’s ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer first discovered at The Wistar Institute, with the study enrolling women who have progressed after at least two…

Continue Reading

WednesdayFeb 25, 2026 9:30 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Expanded IIA Grant Support for Robotic Aseptic Fill & Finish Platform

Scinai Immunotherapeutics (NASDAQ: SCNI) announced that, following additional review by the Israel Innovation Authority, its project to advance a robotic aseptic fill & finish platform has been approved for expanded support, allowing the company to utilize the full approved grant budget of NIS 5 million over two years, approximately 66% of which is non-dilutive funding. The program supports acquisition and validation of a fully automated robotic-arm aseptic fill & finish system aligned with EU GMP Annex 1 standards, with validation targeted for the third quarter of 2026. The investment supports Scinai’s broader CDMO expansion strategy following its acquisition of Recipharm…

Continue Reading

WednesdayFeb 25, 2026 9:10 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in March Investor Conferences

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach. To view the full press release, visit https://ibn.fm/TToz2 Tonix Pharmaceuticals…

Continue Reading

WednesdayFeb 25, 2026 9:09 am

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports Multi-Pillar Clinical and Commercial Progress 

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, provided a consolidated update highlighting recent clinical and commercial progress across its key platforms. The company highlighted submission of a manuscript for peer review, showcasing both a new method, Capture-Seq, and new biomarkers for the detection of cancer, which it estimates represents an annualized total addressable market opportunity of approximately $23 billion. Commercialization of the Nu.Q Cancer assay progressed in lung cancer, with the company reporting reimbursement submission in France on track, and routine clinical use expected by Q4 2026. Volition also confirmed inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France for early detection of sepsis and further highlighted new clinical utility data for its assay in Hidradenitis Suppurativa, noting CE-marked availability across Europe. The company…

Continue Reading

TuesdayFeb 24, 2026 9:20 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit

Soligenix (NASDAQ: SNGX) announced that Christopher J. Schaber, Ph.D., president and chief executive officer, will deliver a corporate presentation at the BIO Investment & Growth Summit at 3 p.m. on March 2. The conference, scheduled for March 2-3 at Eden Roc Miami Beach in Miami Beach, Florida, will feature company presentations, one-on-one meetings and programming focused on growth-stage biotechnology companies. Additional information is available on the conference website. To view the full press release, visit https://ibn.fm/sOzzL About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical…

Continue Reading

MondayFeb 23, 2026 1:25 pm

BioMedNewsBreaks — HeartSciences Inc. (NASDAQ: HSCS; HSCSW) Secures UWE As Exclusive ECG Education Reference Center 

HeartSciences (NASDAQ: HSCS; HSCSW), a healthcare information technology company advancing electrocardiography through artificial intelligence integration, announced that the University of the West of England has adopted its MyoVista Insights(TM) platform and MyoVista(R) wavECG(TM) device as exclusive ECG technologies to establish an ECG Education and Technology Reference Center. Under the agreement, the technologies will be used across UWE’s cardiac and physiological science programs to train future cardiac scientists, creating a nationally aligned academic reference site that supports clinical adoption discussions with NHS trusts, validates MyoVista Insights in education and research settings, and strengthens the company’s long-term commercial positioning within the UK healthcare ecosystem. To view the full press release, visit https://ibn.fm/fkzAO About HeartSciences HeartSciences is a healthcare information…

Continue Reading

MondayFeb 23, 2026 9:40 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A,” highlighting growing investor interest in clinical-stage platforms supported by existing human data. The editorial notes that programs demonstrating clinical activity offer clearer valuation benchmarks and reduced uncertainty compared with preclinical assets, positioning companies with diversified clinical pipelines, including oncology and CNS-focused targets such as TGF-β signaling and delivery-based approaches, to align with industry demand for validated mechanisms and strategic portfolio depth. To view the full press release, visit https://ibn.fm/cZmVn About Oncotelic Therapeutics Inc. Oncotelic Therapeutics…

Continue Reading